AIM： To explore the diffusion gradient b-factor that optimizes both apparent diffusion coefficient （ADC） measurement and contrast-to-noise （CNR） for assessing tumor response to transarterial chemoembolization （T...AIM： To explore the diffusion gradient b-factor that optimizes both apparent diffusion coefficient （ADC） measurement and contrast-to-noise （CNR） for assessing tumor response to transarterial chemoembolization （TACE） in a rabbit model. METHODS： Twelve New Zealand white rabbits bearing VX2 tumors in the liver were treated with TACE. Diffusion-weighted imaging （DWI） with various b values was performed using the same protocol before and 3 d after treatment with TACE. ADC values and CNR of each tumor pre- and post-treatment with different b factors were analyzed. Correlation between ADC values and extent of necrosis in histological specimens was analyzed by a Pearson＇s correlation test.RESULTS： The quality of diffusion-weighted images diminished as the b value increased. A substantial decrease in the mean lesion-to-liver CNR was observed on both pre- and post-treatment DW images, the largest difference in CNR pre- and post-treatment was manifested at a b value of 1000 s/mm^2 （P = 0.036 ）. The effect of therapy on diffusion early after treatment was shown by a significant increase in ADCs （P = 0.007）, especially with large b factors （≥ 600 s/mm^2）. The mean percentage of necrotic cells present within the tumor was 76.3%-97.5%. A significant positive correlation was found between ADC values and the extent of necrosis with all b values except for b200, a higher relative coefficient between ADC values and percentage of necrosis was found on DWI with bl000 and b2000 （P = 0.002 and 0.006, respectively）. CONCLUSION： An increasing b value of up to 600 s/mm^2 would increase ADC contrast pre- and post-treatment, but decrease image quality. Taking into account both CNR and ADC measurement, diffusion-weighted imaging obtained with a b value of 1000 s/mm^2 is recommended for monitoring early hepatic tumor response to TACE.展开更多
AIM： To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastat- ic pancreatic cancer [（frequency, response, outcome, course of carbohydrate antigen 19-9 （CA 19-9）].METHOD...AIM： To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastat- ic pancreatic cancer [（frequency, response, outcome, course of carbohydrate antigen 19-9 （CA 19-9）].METHODS： This retrospective study included all patients with advanced or metastatic pancreatic cancer （adenocarcinoma or carcinoma） treated with secondline chemotherapy in our center between 2000 and 2008. All patients received first-line chemotherapy with gemcitabine, and prior surgery or radiotherapy was permitted. We analyzed each chemotherapy protocol for second-line treatment, the number of cycles and the type of combination used. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, response rate, grade 3-4 toxicity, dosage modifications and CA 19-9 course.a second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabi- ne-based regimen. Median number of cycles was 4 （range： 1-12） and the median duration of treatment was 2.6 mo （range： 0.3-7.4）. The overall disease control rate was 40.0%. The median overall survival and progression-free survival from the start of second-line therapy were 5.8 （95% CI： 4.1-6.6） and 3.4 mo （95% CI： 2.4-4.2）, respectively. Toxicity was generally acceptable. Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo （95% CI： 4.5-11.6） vs 5.2 mo （95% CI： 4.0-6.4） for others （P = 0.008）.CONCLUSION： A large proportion of patients could benefit from second-line therapy, and CA 19-9 allows efficient treatment monitoring both in first and secondline chemotherapy.展开更多
In the fight against cancer, controlled drug delivery systems have emerged to enhance the therapeutic efficacy and safety of anti-cancer drugs. Among these systems, mesoporous silica nanoparticles （MSNs） with a func...In the fight against cancer, controlled drug delivery systems have emerged to enhance the therapeutic efficacy and safety of anti-cancer drugs. Among these systems, mesoporous silica nanoparticles （MSNs） with a functional surface possess obvious advantages and were thus rapidly developed for cancer treatment. Many stimuli-responsive materials, such as nanopartides, polymers, and inorganic materials, have been applied as caps and gatekeepers to control drug release from MSNs. This review presents an overview of the recent progress in the production of pH-responsive MSNs based on the pH gradient between normal tissues and the tumor microenvironment. Four main categories of gatekeepers can respond to acidic conditions. These categories will be described in detail.展开更多
MicroRNAs(miRNAs) are endogenous short non-coding RNAs,and play a pivotal role in regulating a variety of cellular processes,including proliferation and apoptosis,both of which are cellular responses to radiation trea...MicroRNAs(miRNAs) are endogenous short non-coding RNAs,and play a pivotal role in regulating a variety of cellular processes,including proliferation and apoptosis,both of which are cellular responses to radiation treatment.In response to radiation,multiple miRNAs show altered expression,which act as oncogenes or tumor suppressors.Recent evidence has also shown that some miRNAs have radiotherapy sensitization or radiation resistance role in malignant tumors.This review focuses on analysis of these characteristics and mechanisms of miRNAs,and will provide some insight into the therapeutic application of radiation.展开更多
AIM: To clarify the effect of SEN virus (SENV) infection on a combination therapy including interferon alfa (IFN-α) or pegylated-IFN with ribavirin in patients with chronic hepatitis and the effect of a combination t...AIM: To clarify the effect of SEN virus (SENV) infection on a combination therapy including interferon alfa (IFN-α) or pegylated-IFN with ribavirin in patients with chronic hepatitis and the effect of a combination therapy on SENV.METHODS: SENV DNA was determined by polymerase chain reaction in serum samples from 95 patients with chronic hepatitis C. Quantitative analysis was done for SENV H DNA.RESULTS: Twenty-one (22%) of 95 patients were positive for SENV DNA. There was no difference in clinical and biochemical parameters between patients with HCV infection alone and coinfected patients. The sustained response rate for HCV clearance after combination therapy did not differ between patients with SENV (52%) and without SENV(50%, n.s.). SENV DNA was undetectable in 76% of the initially SENV positive patients at the end of follow-up. SENV H response to combination therapy was significantly correlated with SENV DNA level (P=-0.05).CONCLUSION: SENV infection had no influence on the HCV sustained response rate to the combination therapy.Response rate of SENV to the combination therapy depends on SENV DNA level.展开更多
Some patients with perioral dermatitis are not relieved despite many medications. These patients confront pain, psychological bother and social/occupational limitations. Being efficient for a wide variety of diseases ...Some patients with perioral dermatitis are not relieved despite many medications. These patients confront pain, psychological bother and social/occupational limitations. Being efficient for a wide variety of diseases including infectious inflammative degenerative or tumoral, photodynamic therapy holds a good chance to cure diseases of unknown origin, such as perioral dermatitis. This study presents the results of three women with chronic perioral dermatitis that persisted for years with partial response to medical regimen. They asked for photodynamic treatment to ease off their suffering. The duration of follow-up was up to five years. Following PDT （photodynamic therapy）, the patients discontinued medications, redness decreased and eruption disappeared. In these patients, a single PDT treatment provided prolonged relief of perioral dermatitis for up to three years. These data are encouraging but not sufficient. Further study is warranted.展开更多
Objective： The aim of this study was to analyze and compare the recent efficacy and toxicity of a three-drug platinum-based regimen （A regimen）： [cisplatin （DDP） ＋ gemcitabine （GEM） ＋ vinorelbine （NVB）] an...Objective： The aim of this study was to analyze and compare the recent efficacy and toxicity of a three-drug platinum-based regimen （A regimen）： [cisplatin （DDP） ＋ gemcitabine （GEM） ＋ vinorelbine （NVB）] and a two-drug combination without a platinum drug （B regimen）： GEM ＋ NVB, which were used to treat 55 advanced non-small cell lung cancer （NSCLC） patients, in a bid to provide a guidance for clinical treatment. Methods： Twenty-four cases of advanced NSCLC （stage Ill-IV） patients were treated with A regimen （DDP 35 mg/m^2 d1-3; GEM 1250 mg/m^2 d1, 8 ）. The other 31 cases were treated with B （GEM 1250 mg/m^2 d1,8; NVB 25 mg/m^2 d1, 8 ）. Repeat every 3 weeks for 6 courses. Results： In A regimen group, the overall response rate was 45.8% （CR ＋ PR = 11）, median response time was 5.5 months, median survival time was 11 months and 1-year survival rate was 41.7%. In B regimen group, the overall response rate was 48.4% （CR ＋ PR = 15） and median response time, survival time and 1-year survival rate were respectively 6.5 and 10 months and 41.9%. The major toxicities were nausea/vomiting, myelosuppression in A regimen group, myelosuppression and phlebitis in B regimen group, respectively. Conclusion： A regimen and B regimen for advanced NSCLC have similar response rate （P 〉 0.05）. B regimen, a two-drug combination without a platinum drug is of less toxicity and more safety than A regimen, a three-drug platinum-based regimen and is recommended to be a regimen in the first-line treatment for advanced NSCLC.展开更多
目的:评价阿齐沙坦酯(azilsartan medoxomil,AZL-M)治疗原发性高血压的安全性及有效性。方法:检索PubMed、Embase、Cochrane、Web of Science、中国知网、万方、维普等数据库中关于阿齐沙坦酯治疗原发性高血压的随机对照试验,筛选符合...目的:评价阿齐沙坦酯(azilsartan medoxomil,AZL-M)治疗原发性高血压的安全性及有效性。方法:检索PubMed、Embase、Cochrane、Web of Science、中国知网、万方、维普等数据库中关于阿齐沙坦酯治疗原发性高血压的随机对照试验,筛选符合纳入标准的文献并进行文献质量评价,采用RevMan 5.3软件进行Meta分析。结果:共纳入8篇RCT,6148例患者。阿齐沙坦酯治疗组不良事件的发生率无显著性差异(OR=1.03,95%CI:0.94~1.14,P=0.51),导致停药的不良事件发生率也无显著性差异(OR=1.09,95%CI:0.84~1.41,P=0.52)。与其他药物相比,阿齐沙坦酯治疗有更高的收缩压响应率(OR=1.34,95%CI:1.02~1.74,P<0.00001)和血压响应率(OR=2.2,95%CI:1.82~2.66,P<0.00001)。结论:阿齐沙坦酯治疗原发性高血压疗效显著,且不良反应事件的发生率与其他现有治疗药物相当。展开更多
The acidic tumor microenvironment is triggered by glycolysis in hypoxic condition, which can motivate the pHresponsive system to build certain triggers for efficiently tumor-targeted phototherapy. Additionally, the me...The acidic tumor microenvironment is triggered by glycolysis in hypoxic condition, which can motivate the pHresponsive system to build certain triggers for efficiently tumor-targeted phototherapy. Additionally, the metalated porphyrin structures are widely studied in biomedical applications due to the favorable properties of high singlet oxygen quantum yield as well as strong fluorescence imaging ability. Herein, a pH-responsive zinc(II) metalated porphyrin(P-4) was designed and synthesized for amplifying cancer photodynamic/photothermal therapy with excellent fluorescence quantum yield(67.4%), superb singlet oxygen quantum yield(84.3%) and desired photothermal conversion efficiency(30.0%). In vitro, the self-assembled P-4 nanoparticles can specifically target to lysosome subcellular site and realize protonated process of dibutaneaminophenyl(DBAP) groups with high photo toxicity. Under single 660 nm laser illumination, the tumor can be ablated completely with no side effects in vivo. This work demonstrates that the p H-responsive P-4 nanoparticles provide a new avenue for highly efficient cancer combination therapy.展开更多
基金The National Natural Science Foundation of China, NO. 30470503The Key Program of Shanghai Science and Technology Commission, NO. 04JC14074The Foundation of Shanghai Educational commission, NO. 03J405037
文摘AIM： To explore the diffusion gradient b-factor that optimizes both apparent diffusion coefficient （ADC） measurement and contrast-to-noise （CNR） for assessing tumor response to transarterial chemoembolization （TACE） in a rabbit model. METHODS： Twelve New Zealand white rabbits bearing VX2 tumors in the liver were treated with TACE. Diffusion-weighted imaging （DWI） with various b values was performed using the same protocol before and 3 d after treatment with TACE. ADC values and CNR of each tumor pre- and post-treatment with different b factors were analyzed. Correlation between ADC values and extent of necrosis in histological specimens was analyzed by a Pearson＇s correlation test.RESULTS： The quality of diffusion-weighted images diminished as the b value increased. A substantial decrease in the mean lesion-to-liver CNR was observed on both pre- and post-treatment DW images, the largest difference in CNR pre- and post-treatment was manifested at a b value of 1000 s/mm^2 （P = 0.036 ）. The effect of therapy on diffusion early after treatment was shown by a significant increase in ADCs （P = 0.007）, especially with large b factors （≥ 600 s/mm^2）. The mean percentage of necrotic cells present within the tumor was 76.3%-97.5%. A significant positive correlation was found between ADC values and the extent of necrosis with all b values except for b200, a higher relative coefficient between ADC values and percentage of necrosis was found on DWI with bl000 and b2000 （P = 0.002 and 0.006, respectively）. CONCLUSION： An increasing b value of up to 600 s/mm^2 would increase ADC contrast pre- and post-treatment, but decrease image quality. Taking into account both CNR and ADC measurement, diffusion-weighted imaging obtained with a b value of 1000 s/mm^2 is recommended for monitoring early hepatic tumor response to TACE.
文摘AIM： To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastat- ic pancreatic cancer [（frequency, response, outcome, course of carbohydrate antigen 19-9 （CA 19-9）].METHODS： This retrospective study included all patients with advanced or metastatic pancreatic cancer （adenocarcinoma or carcinoma） treated with secondline chemotherapy in our center between 2000 and 2008. All patients received first-line chemotherapy with gemcitabine, and prior surgery or radiotherapy was permitted. We analyzed each chemotherapy protocol for second-line treatment, the number of cycles and the type of combination used. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, response rate, grade 3-4 toxicity, dosage modifications and CA 19-9 course.a second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabi- ne-based regimen. Median number of cycles was 4 （range： 1-12） and the median duration of treatment was 2.6 mo （range： 0.3-7.4）. The overall disease control rate was 40.0%. The median overall survival and progression-free survival from the start of second-line therapy were 5.8 （95% CI： 4.1-6.6） and 3.4 mo （95% CI： 2.4-4.2）, respectively. Toxicity was generally acceptable. Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo （95% CI： 4.5-11.6） vs 5.2 mo （95% CI： 4.0-6.4） for others （P = 0.008）.CONCLUSION： A large proportion of patients could benefit from second-line therapy, and CA 19-9 allows efficient treatment monitoring both in first and secondline chemotherapy.
基金supported by the Chinese Natural Science Foundation Project (Grant No. 30970784 and 81171455)a National Distinguished Young Scholars Grant (Grant No. 31225009) from the National Natural Science Foundation of China+5 种基金the National Key Basic Research Program of China (Grant No. 2009CB930200)the Chinese Academy of Sciences (CAS) ‘Hundred Talents Program’ (Grant No. 07165111ZX)the CAS Knowledge Innovation Program, and the State HighTech Development Plan (Grant No. 2012AA020804)the ‘Strategic Priority Research Program’ of the Chinese Academy of Sciences (Grant No. XDA09030301)NIH/NIMHD 8 G12 MD007597USAMRMC W81XWH-10-1-0767 grants
文摘In the fight against cancer, controlled drug delivery systems have emerged to enhance the therapeutic efficacy and safety of anti-cancer drugs. Among these systems, mesoporous silica nanoparticles （MSNs） with a functional surface possess obvious advantages and were thus rapidly developed for cancer treatment. Many stimuli-responsive materials, such as nanopartides, polymers, and inorganic materials, have been applied as caps and gatekeepers to control drug release from MSNs. This review presents an overview of the recent progress in the production of pH-responsive MSNs based on the pH gradient between normal tissues and the tumor microenvironment. Four main categories of gatekeepers can respond to acidic conditions. These categories will be described in detail.
文摘MicroRNAs(miRNAs) are endogenous short non-coding RNAs,and play a pivotal role in regulating a variety of cellular processes,including proliferation and apoptosis,both of which are cellular responses to radiation treatment.In response to radiation,multiple miRNAs show altered expression,which act as oncogenes or tumor suppressors.Recent evidence has also shown that some miRNAs have radiotherapy sensitization or radiation resistance role in malignant tumors.This review focuses on analysis of these characteristics and mechanisms of miRNAs,and will provide some insight into the therapeutic application of radiation.
文摘AIM: To clarify the effect of SEN virus (SENV) infection on a combination therapy including interferon alfa (IFN-α) or pegylated-IFN with ribavirin in patients with chronic hepatitis and the effect of a combination therapy on SENV.METHODS: SENV DNA was determined by polymerase chain reaction in serum samples from 95 patients with chronic hepatitis C. Quantitative analysis was done for SENV H DNA.RESULTS: Twenty-one (22%) of 95 patients were positive for SENV DNA. There was no difference in clinical and biochemical parameters between patients with HCV infection alone and coinfected patients. The sustained response rate for HCV clearance after combination therapy did not differ between patients with SENV (52%) and without SENV(50%, n.s.). SENV DNA was undetectable in 76% of the initially SENV positive patients at the end of follow-up. SENV H response to combination therapy was significantly correlated with SENV DNA level (P=-0.05).CONCLUSION: SENV infection had no influence on the HCV sustained response rate to the combination therapy.Response rate of SENV to the combination therapy depends on SENV DNA level.
文摘Some patients with perioral dermatitis are not relieved despite many medications. These patients confront pain, psychological bother and social/occupational limitations. Being efficient for a wide variety of diseases including infectious inflammative degenerative or tumoral, photodynamic therapy holds a good chance to cure diseases of unknown origin, such as perioral dermatitis. This study presents the results of three women with chronic perioral dermatitis that persisted for years with partial response to medical regimen. They asked for photodynamic treatment to ease off their suffering. The duration of follow-up was up to five years. Following PDT （photodynamic therapy）, the patients discontinued medications, redness decreased and eruption disappeared. In these patients, a single PDT treatment provided prolonged relief of perioral dermatitis for up to three years. These data are encouraging but not sufficient. Further study is warranted.
文摘Objective： The aim of this study was to analyze and compare the recent efficacy and toxicity of a three-drug platinum-based regimen （A regimen）： [cisplatin （DDP） ＋ gemcitabine （GEM） ＋ vinorelbine （NVB）] and a two-drug combination without a platinum drug （B regimen）： GEM ＋ NVB, which were used to treat 55 advanced non-small cell lung cancer （NSCLC） patients, in a bid to provide a guidance for clinical treatment. Methods： Twenty-four cases of advanced NSCLC （stage Ill-IV） patients were treated with A regimen （DDP 35 mg/m^2 d1-3; GEM 1250 mg/m^2 d1, 8 ）. The other 31 cases were treated with B （GEM 1250 mg/m^2 d1,8; NVB 25 mg/m^2 d1, 8 ）. Repeat every 3 weeks for 6 courses. Results： In A regimen group, the overall response rate was 45.8% （CR ＋ PR = 11）, median response time was 5.5 months, median survival time was 11 months and 1-year survival rate was 41.7%. In B regimen group, the overall response rate was 48.4% （CR ＋ PR = 15） and median response time, survival time and 1-year survival rate were respectively 6.5 and 10 months and 41.9%. The major toxicities were nausea/vomiting, myelosuppression in A regimen group, myelosuppression and phlebitis in B regimen group, respectively. Conclusion： A regimen and B regimen for advanced NSCLC have similar response rate （P 〉 0.05）. B regimen, a two-drug combination without a platinum drug is of less toxicity and more safety than A regimen, a three-drug platinum-based regimen and is recommended to be a regimen in the first-line treatment for advanced NSCLC.
文摘目的:评价阿齐沙坦酯(azilsartan medoxomil,AZL-M)治疗原发性高血压的安全性及有效性。方法:检索PubMed、Embase、Cochrane、Web of Science、中国知网、万方、维普等数据库中关于阿齐沙坦酯治疗原发性高血压的随机对照试验,筛选符合纳入标准的文献并进行文献质量评价,采用RevMan 5.3软件进行Meta分析。结果:共纳入8篇RCT,6148例患者。阿齐沙坦酯治疗组不良事件的发生率无显著性差异(OR=1.03,95%CI:0.94~1.14,P=0.51),导致停药的不良事件发生率也无显著性差异(OR=1.09,95%CI:0.84~1.41,P=0.52)。与其他药物相比,阿齐沙坦酯治疗有更高的收缩压响应率(OR=1.34,95%CI:1.02~1.74,P<0.00001)和血压响应率(OR=2.2,95%CI:1.82~2.66,P<0.00001)。结论:阿齐沙坦酯治疗原发性高血压疗效显著,且不良反应事件的发生率与其他现有治疗药物相当。
基金supported by the National Natural Science Foundation of China(61525402,61775095 and 21704043)Jiangsu Provincial Key Research and Development Plan(BE2017741)+1 种基金Six Talent Peak Innovation Team in Jiangsu Province(TD-SWYY-009)the Natural Science Foundation of Jiangsu Province(BK20170990and 17KJB150020)
文摘The acidic tumor microenvironment is triggered by glycolysis in hypoxic condition, which can motivate the pHresponsive system to build certain triggers for efficiently tumor-targeted phototherapy. Additionally, the metalated porphyrin structures are widely studied in biomedical applications due to the favorable properties of high singlet oxygen quantum yield as well as strong fluorescence imaging ability. Herein, a pH-responsive zinc(II) metalated porphyrin(P-4) was designed and synthesized for amplifying cancer photodynamic/photothermal therapy with excellent fluorescence quantum yield(67.4%), superb singlet oxygen quantum yield(84.3%) and desired photothermal conversion efficiency(30.0%). In vitro, the self-assembled P-4 nanoparticles can specifically target to lysosome subcellular site and realize protonated process of dibutaneaminophenyl(DBAP) groups with high photo toxicity. Under single 660 nm laser illumination, the tumor can be ablated completely with no side effects in vivo. This work demonstrates that the p H-responsive P-4 nanoparticles provide a new avenue for highly efficient cancer combination therapy.
